A Study of CSCJC3456 in Patients With Advanced Malignant Tumors
Status:
RECRUITING
Trial end date:
2028-06-30
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open phase I clinical study of dose escalation, cohort expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CSCJC3456 in patients with advanced malignant solid tumors.
Phase:
PHASE1
Details
Lead Sponsor:
Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.